Cite
HARVARD Citation
Galazka, A. et al. (2018). 040 An analysis of malignancy risk in the clinical development programme of cladribine tablets in patients with relapsing multiple sclerosis. Journal of neurology, neurosurgery and psychiatry. 89 (6), p. A17. [Online].